answer text |
<p>Figures provided for Primary Care for total drug spend are the total of net ingredient
cost (NIC) and for Secondary Care the cost of the medicines at NHS list price.</p><p>
</p><p> </p><p> </p><p> </p><table><tbody><tr><td colspan="6"><p>Cost of drugs in
primary and secondary care, England: 2009-10 to 2013-14</p></td></tr><tr><td><p>Total
drugs</p></td><td colspan="4"><p> </p></td><td><p>Cost (£ million)</p></td></tr><tr><td><p>
</p></td><td colspan="2"><p>Primary Care<sup>1</sup></p></td><td colspan="2"><p>Secondary
Care<sup>2</sup></p></td><td><p>Total</p></td></tr><tr><td><p>2009-10</p></td><td
colspan="2"><p>8,621.4</p></td><td colspan="2"><p>3,890.8</p></td><td><p>12,512.2</p></td></tr><tr><td><p>2010-11</p></td><td
colspan="2"><p>8,881.1</p></td><td colspan="2"><p>4,173.9</p></td><td><p>13,055.0</p></td></tr><tr><td><p>2011-12</p></td><td
colspan="2"><p>8,778.0</p></td><td colspan="2"><p>4,497.6</p></td><td><p>13,275.5</p></td></tr><tr><td><p>2012-13</p></td><td
colspan="2"><p>8,439.0</p></td><td colspan="2"><p>5,020.8</p></td><td><p>13,459.8</p></td></tr><tr><td><p>2013-14</p></td><td
colspan="2"><p>8,703.2</p></td><td colspan="2"><p>5,780.6</p></td><td><p>14,483.8</p></td></tr><tr><td
colspan="6"><p><em>Sources:</em> Prescription Cost Analysis (PCA), IMS HEALTH: Hospital
Pharmacy Audit</p></td></tr><tr><td colspan="6"><p>Cost of cancer drugs<sup>3 </sup>in
primary and secondary care, England: 2009-10 to 2013-14</p></td></tr><tr><td><p>Total
drugs</p></td><td colspan="4"><p> </p></td><td><p>Cost (£ million)</p></td></tr><tr><td><p>
</p></td><td colspan="2"><p>Primary Care<sup>1,4</sup></p></td><td colspan="2"><p>Secondary
Care<sup>2</sup></p></td><td><p>Total</p></td></tr><tr><td><p>2009-10</p></td><td
colspan="2"><p>230.2</p></td><td colspan="2"><p>748.1</p></td><td><p>978.3</p></td></tr><tr><td><p>2010-11</p></td><td
colspan="2"><p>228.2</p></td><td colspan="2"><p>846.1</p></td><td><p>1,074.3</p></td></tr><tr><td><p>2011-12</p></td><td
colspan="2"><p>190.0</p></td><td colspan="2"><p>964.1</p></td><td><p>1,154.1</p></td></tr><tr><td><p>2012-13</p></td><td
colspan="2"><p>142.0</p></td><td colspan="2"><p>1,119.6</p></td><td><p>1,261.6</p></td></tr><tr><td><p>2013-14</p></td><td
colspan="2"><p>143.0</p></td><td colspan="2"><p>1,350.2</p></td><td><p>1,493.2</p></td></tr><tr><td
colspan="6"><p><em>Sources:</em> PCA, IMS HEALTH: Hospital Pharmacy Audit</p></td></tr><tr><td
colspan="4"><p>Spend through the Cancer Drugs Fund between October 2010 and March
2014</p></td><td colspan="2"><p> </p></td></tr><tr><td colspan="2"><p>Year</p></td><td
colspan="2"><p>Spend (£000’s)</p></td><td colspan="2"><p> </p></td></tr><tr><td colspan="2"><p>2010-11
(Q3 and Q4)</p></td><td colspan="2"><p>38,254</p></td><td colspan="2"><p> </p></td></tr><tr><td
colspan="2"><p>2011-12</p></td><td colspan="2"><p>108,327</p></td><td colspan="2"><p>
</p></td></tr><tr><td colspan="2"><p>2012-13</p></td><td colspan="2"><p>175,334</p></td><td
colspan="2"><p> </p></td></tr><tr><td colspan="2"><p>2013-14</p></td><td colspan="2"><p>230,539</p></td><td
colspan="2"><p> </p></td></tr><tr><td> </td><td> </td><td> </td><td> </td><td> </td><td>
</td></tr></tbody></table><p> </p><p><em>Source:</em> Prior to April 2013, information
supplied to the Department by strategic health authorities. From April 2013, information
supplied by NHS England.</p><p> </p><p> </p><p> </p><p><em>Notes:</em></p><p> </p><p><sup>1
</sup>Primary Care NIC is the basic cost of the drug, which does not take account
of discounts, dispensing costs, fees or prescription charges income.</p><p> </p><p><sup>2
</sup>Secondary care cost is the cost of the medicines at NHS list price which may
not reflect the price the hospital paid.</p><p> </p><p><sup>3 </sup>Cancer drugs are
defined by British National Formulary Sections 8.1 <em>Cytotoxic drugs</em>,</p><p>
</p><p>8.2.3 <em>Anti-lymphocyte monoclonal antibodies</em> (but also used in other
indications), 8.2.4 <em>Other immunomodulating drugs</em> (Interferon-Alfa, Aldesleukin,
Bacillus Calmette-Guerin (B.C.G.), Lenalidomide, Pomalidomide, Thalidomide and Mifamurtide
only), and 8.3 <em>Sex hormones and hormone antagonists in malignant disease</em>.</p><p>
</p><p><sup>4 </sup>The main reason for the reduction in cancer drugs in Primary Care
is the introduction of lower cost generic formulations.</p><p> </p><p> </p><p> </p>
|
|